<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03042429</url>
  </required_header>
  <id_info>
    <org_study_id>UCologne</org_study_id>
    <nct_id>NCT03042429</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients</brief_title>
  <acronym>NB2004-HR</acronym>
  <official_title>Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-risk Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improvement of event free survival of high-risk neuroblastoma patients by introduction of two
      additional topotecan containing chemotherapy cycles into the multimodal standard treatment
      (induction chemotherapy, myeloablative therapy, radiation, surgery as indicated, and
      consolidation therapy).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental intervention (6 weeks + duration of the control intervention):

      2 x N8 cycle (topotecan, cyclophosphamide, and etoposide) followed by standard arm treatment
      (i.e., control intervention)

      Control intervention (total duration 70-76 weeks):

      3 x N5 cycle (cisplatin, etoposide, and vindesine) 3 x N6 cycle (vincristine, dacarbacine,
      ifosfamide, and doxorubicine), myeloablative chemotherapy with autologous stem cell
      transplantation (melphalan, carboplatin, etoposide) 9 x retinoic acid cycles (6 months, 3
      months break, 3 months) supportive care (PCP/fungal prophylaxis, transfusions, antibiotics,
      G-CSF)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2007</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Randomized, multi-center, non-blinded, prospective, controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>no masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>up to 9 years</time_frame>
    <description>days from diagnosis to Event or last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 9 years</time_frame>
    <description>days from diagnosis to death or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>early response</measure>
    <time_frame>up to 3 months</time_frame>
    <description>remission status (INRG) measured after 2 chemotherapy cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late response</measure>
    <time_frame>up to 9 months</time_frame>
    <description>remission status (INRG) measured before stem cell transplant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Cycles N8, N5, and N6 Drug: topotecan, cyclophosphamide, and etoposide (N8 cycle) followed by Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Cycles N5 and N6 Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycles N8, N5 and N6</intervention_name>
    <description>two chemotherapy cycles N8 followed by standard arm therapy</description>
    <arm_group_label>experimental arm</arm_group_label>
    <other_name>topotecan, cyclophosphamide, etoposide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycles N5 and N6</intervention_name>
    <description>Standard arm six chemotherapy cycles (3xN5 and 3x N6) followed by myeloablative therapy with stem cell support and isotretinoin</description>
    <arm_group_label>standard arm</arm_group_label>
    <other_name>cisplatin, vindesine, ifosfamide, dacarbacine, doxorubicine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  neuroblastoma

          -  stage 4 neuroblastoma and age ≥1 - 21 years or MYCN amplification and age ≥6 months -
             21 years

          -  informed consent obtained

        Exclusion Criteria:

          -  Participation in other trials

          -  Pregnancy, lactation, or insufficient contraception for girls in childbearing age,

          -  Any concomitant non-protocol anticancer therapy,

          -  Incomplete initial staging.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Berthold, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Koln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, Schrappe M, Simon T, Spix C. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett. 2003 Jul 18;197(1-2):11-7.</citation>
    <PMID>12880954</PMID>
  </results_reference>
  <results_reference>
    <citation>Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, Simon T, Hero B. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005 Sep;6(9):649-58.</citation>
    <PMID>16129365</PMID>
  </results_reference>
  <results_reference>
    <citation>Längler A, Christaras A, Abshagen K, Krauth K, Hero B, Berthold F. Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study. Klin Padiatr. 2002 Jul-Aug;214(4):153-6.</citation>
    <PMID>12165894</PMID>
  </results_reference>
  <results_reference>
    <citation>Berthold F, Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs. 2000 Jun;59(6):1261-77. Review.</citation>
    <PMID>10882162</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2017</study_first_submitted>
  <study_first_submitted_qc>February 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2017</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Frank Berthold</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>neuroblastoma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>mIBG</keyword>
  <keyword>tumor resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Vindesine</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

